285 related articles for article (PubMed ID: 8847891)
21. Lipid-based formulations of amphotericin B.
Veerareddy PR; Vobalaboina V
Drugs Today (Barc); 2004 Feb; 40(2):133-45. PubMed ID: 15045035
[TBL] [Abstract][Full Text] [Related]
22. Nephrotoxicity and other adverse events among inpatients receiving liposomal amphotericin B or amphotericin B lipid complex.
Wade RL; Chaudhari P; Natoli JL; Taylor RJ; Nathanson BH; Horn DL
Diagn Microbiol Infect Dis; 2013 Jul; 76(3):361-7. PubMed ID: 23774005
[TBL] [Abstract][Full Text] [Related]
23. Liposome battle for antifungal market shifts into high gear.
Marks S
J Int Assoc Physicians AIDS Care; 1996 Apr; 2(4):46-7. PubMed ID: 11363518
[TBL] [Abstract][Full Text] [Related]
24. Amphotericin B lipid preparations: what are the differences?
Adler-Moore JP; Proffitt RT
Clin Microbiol Infect; 2008 May; 14 Suppl 4():25-36. PubMed ID: 18430127
[TBL] [Abstract][Full Text] [Related]
25. A systematic review of the antifungal effectiveness and tolerability of amphotericin B formulations.
Barrett JP; Vardulaki KA; Conlon C; Cooke J; Daza-Ramirez P; Evans EG; Hawkey PM; Herbrecht R; Marks DI; Moraleda JM; Park GR; Senn SJ; Viscoli C;
Clin Ther; 2003 May; 25(5):1295-320. PubMed ID: 12867214
[TBL] [Abstract][Full Text] [Related]
26. Lipid formulations of amphotericin B as first-line treatment of zygomycosis.
Petrikkos GL
Clin Microbiol Infect; 2009 Oct; 15 Suppl 5():87-92. PubMed ID: 19754765
[TBL] [Abstract][Full Text] [Related]
27. Development of liposomal amphotericin B formulation.
Gulati M; Bajad S; Singh S; Ferdous AJ; Singh M
J Microencapsul; 1998; 15(2):137-51. PubMed ID: 9532520
[TBL] [Abstract][Full Text] [Related]
28. The reformulation of amphotericin B for oral administration to treat systemic fungal infections and visceral leishmaniasis.
Thornton SJ; Wasan KM
Expert Opin Drug Deliv; 2009 Mar; 6(3):271-84. PubMed ID: 19327044
[TBL] [Abstract][Full Text] [Related]
29. Use of liposomal amphotericin B in bone marrow transplant.
Sastry PS; Parikh PM; Kulkarni PS; Bhagwat R; Gadade H
J Postgrad Med; 2005; 51 Suppl 1():S49-52. PubMed ID: 16519256
[TBL] [Abstract][Full Text] [Related]
30. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group.
Walsh TJ; Finberg RW; Arndt C; Hiemenz J; Schwartz C; Bodensteiner D; Pappas P; Seibel N; Greenberg RN; Dummer S; Schuster M; Holcenberg JS
N Engl J Med; 1999 Mar; 340(10):764-71. PubMed ID: 10072411
[TBL] [Abstract][Full Text] [Related]
31. Renal impairment and amphotericin B formulations in patients with invasive fungal infections.
Saliba F; Dupont B
Med Mycol; 2008 Mar; 46(2):97-112. PubMed ID: 18324488
[TBL] [Abstract][Full Text] [Related]
32. A brain-vectored angiopep-2 based polymeric micelles for the treatment of intracranial fungal infection.
Shao K; Wu J; Chen Z; Huang S; Li J; Ye L; Lou J; Zhu L; Jiang C
Biomaterials; 2012 Oct; 33(28):6898-907. PubMed ID: 22789719
[TBL] [Abstract][Full Text] [Related]
33. Lipid-based antifungal agents: current status.
Arikan S; Rex JH
Curr Pharm Des; 2001 Mar; 7(5):393-415. PubMed ID: 11254895
[TBL] [Abstract][Full Text] [Related]
34. Lipid formulations of amphotericin B: recent progress and future directions.
Hiemenz JW; Walsh TJ
Clin Infect Dis; 1996 May; 22 Suppl 2():S133-44. PubMed ID: 8722841
[TBL] [Abstract][Full Text] [Related]
35. Amphotericin B lipid complex to treat invasive fungal infections in cancer patients: report of efficacy and safety in 20 patients.
Oravcová E; Mistrík M; Sakalová A; Drgona L; Kollár T; Helpianska L; Ilavská I; Sorkovská D; Spánik S; Kukucková E
Chemotherapy; 1995; 41(6):473-6. PubMed ID: 8529439
[TBL] [Abstract][Full Text] [Related]
36. Efficacy of amphotericin B lipid complex injection (ABLC) in bone marrow transplant recipients with life-threatening systemic mycoses.
Wingard JR
Bone Marrow Transplant; 1997 Feb; 19(4):343-7. PubMed ID: 9051244
[TBL] [Abstract][Full Text] [Related]
37. What is the current and future status of conventional amphotericin B?
Kleinberg M
Int J Antimicrob Agents; 2006 Jun; 27 Suppl 1():12-6. PubMed ID: 16707251
[TBL] [Abstract][Full Text] [Related]
38. The lipid formulations of amphotericin B.
Herbrecht R; Natarajan-Amé S; Nivoix Y; Letscher-Bru V
Expert Opin Pharmacother; 2003 Aug; 4(8):1277-87. PubMed ID: 12877636
[TBL] [Abstract][Full Text] [Related]
39. Amphotericin B deoxycholate (d-AMB) use in cases with febrile neutropenia and fungal infections: lower toxicity with suitable premedication.
Oto OA; Paydas S; Disel U; Yavuz S; Seydaoglu G
Mycoses; 2007 Mar; 50(2):135-9. PubMed ID: 17305778
[TBL] [Abstract][Full Text] [Related]
40. Low-dose amphotericin for prevention of serious fungal infection following liver transplantation.
Shah T; Lai WK; Gow P; Leeming J; Mutimer D
Transpl Infect Dis; 2005; 7(3-4):126-32. PubMed ID: 16390401
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]